Compare F5 Inc (FFIV) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Medpace Holdings Inc — how do they compare? F5 Inc trades at $419.01 (market cap $23.44B), while Medpace Holdings Inc trades at $597.55 (market cap $16.90B). The key difference: F5 Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| FFIV | MEDP | |
|---|---|---|
Market Cap | $23.44B | $16.90B |
Sector | Technology | Technology |
52-Week High | $431.26 | $620.59 |
52-Week Low | $223.99 | $393.42 |
Enterprise Value | $22.08B | $16.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $414.00, up 0.98% in the last session, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $3.09 billion in 2025, with a net income margin of 21.95%, while the company raised its annual revenue forecast on robust cybersecurity demand (Reuters, 2026-07-27). The stock is near resistance at $417, with RSI indicating mild overbought conditions.
The outlook remains positive due to consistent earnings outperformance and AI-driven security growth, but risks include high valuation multiples (P/E of 32.98) and competitive pressures. Analysts maintain a moderate buy consensus with a $430.43 price target, suggesting potential upside from current levels.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
